Concepedia

Anmol Gulati

AG

Statistics

Publications

7

Citations

405

H-Index

7

Active since

2013

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Institut Pasteur Korea

University of Illinois Urbana-Champaign

United States Military Academy

Colorado State University

Anmol Gulati is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

ORCID

Publications per year

2013–2023

7

Publications

7

Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases

Kai Li, Lici A. Schurig-Briccio, Xinxin Feng et al. · Journal of Medicinal Chemistry · 2014 · 227 citations · Full text

, , +17

Chemo-Immunotherapeutic Antimalarials Targeting Isoprenoid Biosynthesis

Yonghui Zhang, Wei Zhu, Yi-Liang Liu et al. · ACS Medicinal Chemistry Letters · 2013 · 42 citations · Full text

, , +16

Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors

Mitchell H. Keylor, Anmol Gulati, Solomon D. Kattar et al. · Journal of Medicinal Chemistry · 2021 · 42 citations · Full text

, , +17

Oxa, Thia, Heterocycle, and Carborane Analogues of SQ109: Bacterial and Protozoal Cell Growth Inhibitors

Kai Li, Yang Wang, Gyongseon Yang et al. · ACS Infectious Diseases · 2015 · 37 citations · Full text

, , +15

Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 <i>H</i> -Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease

David A. Candito, Vladimir Simov, Anmol Gulati et al. · Journal of Medicinal Chemistry · 2022 · 24 citations · Full text

, , +15

1–5 of 7